Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Scholar Rock Holding Corporation (SRRK : NSDQ)
 
 • Company Description   
Scholar Rock Holding Corporation is a biopharmaceutical company. It focused on the discovery and development of medicines for treatment of serious diseases. The company's product candidate includes SRK-015 and BMP6 which is in pre-clinical stage. Scholar Rock Holding Corporation is based in Cambridge, United States.

Number of Employees: 145

 
 • Price / Volume Information   
Yesterday's Closing Price: $5.29 Daily Weekly Monthly
20 Day Moving Average: 679,994 shares
Shares Outstanding: 35.30 (millions)
Market Capitalization: $186.75 (millions)
Beta: 0.60
52 Week High: $44.95
52 Week Low: $4.84
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -40.43% -34.77%
12 Week -69.19% -65.37%
Year To Date -78.70% -73.98%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
301 BINNEY STREET 3RD FLOOR
-
CAMBRIDGE,MA 02142
USA
ph: 857-259-3860
fax: 866-493-4935
stephanie.ascher@sternir.com http://www.scholarrock.com
 
 • General Corporate Information   
Officers
Nagesh K. Mahanthappa - Chief Executive Officer and President
David Hallal - Chairman of the Board of Directors
Edward H. Myles - Chief Operating Officer & Chief Financial Officer
Kristina Burow - Director
Jeffrey S. Flier - Director

Peer Information
Scholar Rock Holding Corporation (CORR.)
Scholar Rock Holding Corporation (RSPI)
Scholar Rock Holding Corporation (CGXP)
Scholar Rock Holding Corporation (BGEN)
Scholar Rock Holding Corporation (GTBP)
Scholar Rock Holding Corporation (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 80706P103
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/09/22
Share - Related Items
Shares Outstanding: 35.30
Most Recent Split Date: (:1)
Beta: 0.60
Market Capitalization: $186.75 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.02 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.16 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/09/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.09
Price/Cash Flow: -
Price / Sales: 3.95
EPS Growth
vs. Year Ago Period: 72.37%
vs. Previous Quarter: 78.35%
Sales Growth
vs. Year Ago Period: 605.03%
vs. Previous Quarter: 719.78%
ROE
03/31/22 - -59.99
12/31/21 - -64.57
09/30/21 - -54.11
ROA
03/31/22 - -37.33
12/31/21 - -40.69
09/30/21 - -35.51
Current Ratio
03/31/22 - 6.85
12/31/21 - 4.13
09/30/21 - 4.00
Quick Ratio
03/31/22 - 6.85
12/31/21 - 4.13
09/30/21 - 4.00
Operating Margin
03/31/22 - -236.95
12/31/21 - -700.46
09/30/21 - -672.72
Net Margin
03/31/22 - -236.95
12/31/21 - -700.46
09/30/21 - -672.72
Pre-Tax Margin
03/31/22 - -236.95
12/31/21 - -700.46
09/30/21 - -672.72
Book Value
03/31/22 - 4.85
12/31/21 - 4.90
09/30/21 - 5.43
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.25
12/31/21 - 0.28
09/30/21 - 0.13
Debt-to-Capital
03/31/22 - 20.29
12/31/21 - 21.96
09/30/21 - 11.75
 

Powered by Zacks Investment Research ©